Tradewind BioScience GTM brain

category

market profile

• text: The EGFL6 antibody program has published preclinical results; present clinical status remains uncertain.
• text: Platinum-resistant ovarian cancer has established and emerging treatment alternatives with different targets and evidence.

personas

• title: Oncology pharmaceutical business development lead
  pains:

  • Finding differentiated early oncology assets
  • Assessing translational, manufacturing and clinical risks before licensing
• title: Gynecologic oncology clinical investigator
  pains:

  • Limited treatment options in recurrent platinum-resistant disease
  • Need for credible safety, biomarker and human efficacy data
• title: Biotech investor
  pains:

  • Funding development through first human studies
  • Assessing whether preclinical activity translates to patients

icp

• text: Oncology-focused pharmaceutical companies with antibody development and licensing capabilities are plausible partners, not confirmed customers.
• text: Academic cancer centers with ovarian cancer and translational research programs are potential collaborators.

message pillars

• text: Develop therapies for aggressive cancers.
• text: Translate founder science into drugs.
• text: Identify patients likely to benefit through biomarkers.

objections

• objection: Is there evidence of benefit in people?
  response: Present published preclinical evidence and verified trial status without implying approval or human efficacy.
• objection: How is this differentiated from available therapies?
  response: Explain the EGFL6 approach and proposed biomarker strategy while recognizing different indications and evidence levels.

competitors

• name: AbbVie
  why: Elahere is an established biomarker-directed ovarian cancer treatment, with a different target and clinical status.
• name: Corcept Therapeutics
  why: Develops treatment for platinum-resistant ovarian cancer, a potential treatment alternative.

influencers

• name: Ron Buckanovich
  url: https://tradewindbio.com/team
  why: Scientific cofounder and ovarian cancer researcher.

keywords

• EGFL6 ovarian cancer antibody
• platinum resistant ovarian cancer therapy
• ovarian cancer biomarker
• oncology antibody licensing
• ovarian cancer immunotherapy

voice

• Scientific
• Mission-led
• Patient-focused

signals

• text: A pharmaceutical company seeks early ovarian cancer antibodies for partnership or licensing.
• text: An academic group is recruiting partners for translational ovarian cancer research.

pricing

motion

channels

• Scientific publications
• Biotech investor showcases

confidence

Founders

• name: Thaddeus Allen
  title: Founder/CEO
  role: CEO
  bio: As a full-time founder at Tradewind, my focus is on translating novel science into viable and novel therapeutic approaches and relating the value of our mission. This calls on skills and knowledge developed through 25 years of cancer research experience and more recent experience in business oriented rolls. Skills/Experience - PhD level cancer biologist - Management of a research team - Patent portfolio management and IP agreements - Scientific data analysis and interpretation